和晶科技(300279.SZ):和晶宏智擬出資250萬元與專業投資機構共設基金管理公司
格隆匯7月26日丨和晶科技(300279.SZ)公佈,公司全資子公司北京和晶宏智產業投資有限公司(“和晶宏智”)與浩鯨雲計算科技股份有限公司(“浩鯨科技”)、國信曙光生態技術研究院(北京)有限公司(“國信曙光”)、睿合致遠(深圳)企業管理合夥企業(有限合夥)(“睿合致遠”)於2021年7月26日簽署《睿合私募股權基金管理(深圳)管理有限公司合資協議》,各方計劃共同投資人民幣1000萬元設立睿合私募股權基金管理(深圳)管理有限公司(“基金管理公司”、“標的公司”),其中和晶宏智、浩鯨科技、國信曙光、睿合致遠分別出資250萬元,出資比例均為25%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.